|
Secondary prevention
Citations 291-300 of 568 total displayed.
|
Past content
(since Feb 1999):
|
- Reviews: Current Perspectives
Principles for National and Regional Guidelines on Cardiovascular Disease Prevention: A Scientific Statement From the World Heart and Stroke Forum
- Sidney C. Smith, Jr, Rod Jackson, Thomas A. Pearson, Valentin Fuster, Salim Yusuf, Ole Faergeman, David A. Wood, Michael Alderman, John Horgan, Philip Home, Marilyn Hunn, and Scott M. Grundy
Circulation 2004;109:3112-3121, doi:10.1161/01.CIR.0000133427.35111.67
[Full text]
- Articles
Heart Failure and Sudden Death in Patients With Tachycardia-Induced Cardiomyopathy and Recurrent Tachycardia
- Pamela Nerheim, Sally Birger-Botkin, Lubna Piracha, and Brian Olshansky
Circulation published June 28, 2004, doi:10.1161/01.CIR.0000135472.28234.CC
[Abstract]
- Clinical Investigations and Reports
Nonsteroidal Antiinflammatory Drugs and the Risk of Myocardial Infarction in the General Population
- Luis A. García Rodríguez, Cristina Varas-Lorenzo, Andrew Maguire, and Antonio González-Pérez
Circulation 2004;109:3000-3006; published online before print as doi:10.1161/01.CIR.0000132491.96623.04
[Abstract]
[Full text]
- Articles
Nonsteroidal Antiinflammatory Drugs and the Risk of Myocardial Infarction in the General Population
- Luis A. García Rodríguez, Cristina Varas-Lorenzo, Andrew Maguire, and Antonio González-Pérez
Circulation published June 14, 2004, doi:10.1161/01.CIR.0000132491.96623.04
[Abstract]
- Review: Current Perspective
Bidirectional Relation Between Inflammation and Coagulation
- Marcel Levi, Tom van der Poll, and Harry R. Büller
Circulation 2004;109:2698-2704, doi:10.1161/01.CIR.0000131660.51520.9A
[Full text]
- AHA Conference Proceedings
Atherosclerotic Vascular Disease Conference: Executive Summary: Atherosclerotic Vascular Disease Conference Proceeding for Healthcare Professionals From a Special Writing Group of the American Heart Association
- David P. Faxon, Mark A. Creager, Sidney C. Smith, Jr, Richard C. Pasternak, Jeffrey W. Olin, Michael A. Bettmann, Michael H. Criqui, Richard V. Milani, Joseph Loscalzo, John A. Kaufman, Daniel W. Jones, and William H. Pearce
Circulation 2004;109:2595-2604, doi:10.1161/01.CIR.0000128517.52533.DB
[Full text]
- AHA Conference Proceedings
Atherosclerotic Vascular Disease Conference: Writing Group V: Medical Decision Making and Therapy
- Mark A. Creager, Daniel W. Jones, J. Donald Easton, Jonathan L. Halperin, Alan T. Hirsch, Alan H. Matsumoto, Patrick T. O’Gara, Robert D. Safian, Gary L. Schwartz, and John A. Spittell
Circulation 2004;109:2634-2642, doi:10.1161/01.CIR.0000128522.98016.19
[Full text]
- Clinical Investigations and Reports
Growth Hormone Replacement Decreases Plasma Levels of Matrix Metalloproteinases (2 and 9) and Vascular Endothelial Growth Factor in Growth Hormone–Deficient Individuals
- Harpal S. Randeva, Krzysztof C. Lewandowski, Jan Komorowski, Robert D. Murray, Chris J. O’Callaghan, Edward W. Hillhouse, Henryk Stepien, and Stephen M. Shalet
Circulation 2004;109:2405-2410; published online before print as doi:10.1161/01.CIR.0000129763.51060.77
[Abstract]
[Full text]
- Clinical Investigations and Reports
Peroxisome Proliferator–Activated Receptor Ligand Bezafibrate for Prevention of Type 2 Diabetes Mellitus in Patients With Coronary Artery Disease
- Alexander Tenenbaum, Michael Motro, Enrique Z. Fisman, Ehud Schwammenthal, Yehuda Adler, Ilan Goldenberg, Jonathan Leor, Valentina Boyko, Lori Mandelzweig, and Solomon Behar
Circulation 2004;109:2197-2202; published online before print as doi:10.1161/01.CIR.0000126824.12785.B6
[Abstract]
[Full text]
- Articles
Growth Hormone Replacement Decreases Plasma Levels of Matrix Metalloproteinases (2 and 9) and Vascular Endothelial Growth Factor in Growth Hormone-Deficient Individuals
- Harpal S. Randeva, Krzysztof C. Lewandowski, Jan Komorowski, Robert D. Murray, Chris J. O’Callaghan, Edward W Hillhouse, Henryk Stepien, and Stephen M. Shalet
Circulation published May 3, 2004, doi:10.1161/01.CIR.0000129763.51060.77
[Abstract]
|
|
